These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 33705643)

  • 1. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
    Tran N; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro synergistic effects of various combinations of vancomycin and non-beta-lactams against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Kang YR; Chung DR; Kim J; Baek JY; Kim SH; Ha YE; Kang CI; Peck KR; Song JH
    Diagn Microbiol Infect Dis; 2016 Nov; 86(3):293-299. PubMed ID: 27591174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
    Katayama Y; Murakami-Kuroda H; Cui L; Hiramatsu K
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3190-6. PubMed ID: 19451283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
    Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
    PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
    Leonard SN; Supple ME; Gandhi RG; Patel MD
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.
    Zheng X; Berti AD; McCrone S; Roch M; Rosato AE; Rose WE; Chen B
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.
    Miranda-Novales G; Leaños-Miranda BE; Vilchis-Pérez M; Solórzano-Santos F
    Ann Clin Microbiol Antimicrob; 2006 Oct; 5():25. PubMed ID: 17034644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.
    Werth BJ; Vidaillac C; Murray KP; Newton KL; Sakoulas G; Nonejuie P; Pogliano J; Rybak MJ
    Antimicrob Agents Chemother; 2013 May; 57(5):2376-9. PubMed ID: 23422917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
    Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
    J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.
    Mather CA; Werth BJ; Sivagnanam S; SenGupta DJ; Butler-Wu SM
    J Clin Microbiol; 2016 Apr; 54(4):883-90. PubMed ID: 26763961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.